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? CASE REPORT ?
Severe Ovarian Hyperstimulation Syndrome Complicated
by Stenotrophomonas maltophilia Peritonitis: A Case Report
and Literature Review
Abdul Rehman 1, Noor Ul-Ain Baloch 1 and Muhammad Awais 2
Abstract
Ovarian hyperstimulation syndrome (OHSS) is an iatrogenic disorder resulting from ovulation induction.
Although the occurrence of this disorder is rare, it can be potentially life-threatening in its most severe forms.
We herein present the case of a young nulliparous woman who presented with features of abdominal com-
partment syndrome and was subsequently diagnosed with severe OHSS. All physicians, in particular critical
care doctors, must be aware of this rare, but potentially life-threatening iatrogenic disorder.
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Introduction
Ovarian hyperstimulation syndrome (OHSS) is a well-
recognized, but rare complication of ovulation induction (1).
This iatrogenic complication results from a loss of control
of ovarian stimulation and can occur from any agent used
for ovulation induction (2). The severe form of OHSS is re-
ported to occur in 0.5-5% of stimulated ovarian cycles with
a mortality rate of about 1 in 50,000 (3). We herein report
the case of a young woman who presented with features of
abdominal compartment syndrome and was diagnosed with
severe OHSS.
Case Report
A 28-year-old nulliparous woman presented to the emer-
gency department with complaints of abdominal distension
and shortness of breath. Her medical history included poly-
cystic ovarian syndrome and she has had primary infertility
for the past few years. She could not conceive despite re-
ceiving multiple courses of clomiphene citrate and multiple
injections of human chorionic gonadotropin. On the physical
examination, she was obese with marked tachycardia (150
beats/minute), tachypnea (25 breaths/minute) and dry mu-
cous membranes. She also had a markedly distended abdo-
men with prominent shifting dullness. Initial investigations
revealed a serum creatinine level of 2.2 mg/dL, suggestive
of acute kidney injury, along with a leukoerythroblastic pic-
ture (total leukocyte count of 53,000/mm3). Ultrasonography
of the abdomen confirmed the presence of ascites along
with enlarged polycystic ovaries (Fig. 1). Based on the clini-
cal picture and ultrasonographic evidence, a diagnosis of
OHSS was made.
Foley’s catheter and a central venous line were inserted
and the patient was administered intravenous fluids judi-
ciously. The intra-abdominal pressure was measured indi-
rectly and was found to be significantly elevated. An arterial
blood gas revealed hypoxemia along with hypercarbia for
which she was started on non-invasive positive pressure ven-
tilation. Blood products were arranged and an ultrasound-
guided therapeutic paracentesis was performed, six hours af-
ter arrival to the emergency room, which drained 800 mL of
hemorrhagic fluid. The patient was admitted to the high-
dependency unit and monitored closely. Her condition in-
itially improved after ascitic drainage; however, the patient
then began to spike a fever approximately 20 hours after ar-
rival. She was started on an empirical, renal-adjusted dose
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Figure?1.?A: The longitudinal view of an ultrasonographic image of the right upper quadrant dem-
onstrates the presence of free fluid within the perihepatic and hepatorenal spaces. B: The longitudinal 
view of an ultrasonographic image of the left ovary shows an enlarged, polycystic ovary surrounded 
by free fluid containing echogenic material, suggestive of hemorrhagic ascites.
of piperacillin-tazobactam. A repeat paracentesis was per-
formed, which revealed a neutrophil count of 800/μL sug-
gestive of bacterial peritonitis. The patient’s fever persisted
for the next 48 hours and she was switched to meropenem
and vancomycin after sending blood and urine cultures to
the clinical laboratory. The ascitic fluid culture subsequently
revealed heavy growth of Stenotrophomonas maltophilia
which was sensitive to levofloxacin, minocycline and ceftaz-
idime. The patient was started on intravenous ceftazidime (1
g/12 hours) and continued on supportive care. Gradually, her
fever subsided, intra-abdominal pressure reduced, serum cre-
atinine level returned to baseline, urinary output increased
and her overall condition began to improve. Her blood and
urine cultures did not grow any bacterial pathogens. After
being moved to the general ward, the patient was switched
from intravenous ceftazidime to oral levofloxacin (750 mg,
once daily). She was discharged after a two-week stay in the
hospital following a repeat ultrasound, which documented
the resolution of the ascites. At a 6-month follow-up visit,
the patient remained asymptomatic and now leads a normal
life.
Discussion
OHSS is a purely iatrogenic disorder resulting from un-
controlled ovarian stimulation due to exogenous means of
ovulation induction. The first case of this syndrome was re-
ported back in 1943 (4) and since then, the incidence of this
disorder has increased steadily due to widespread availabil-
ity and use of assisted fertility techniques (5). Although fer-
tility is essential for the propagation of families, it is not vi-
tal for sustaining life. Therefore, the perpetuation of a life-
threatening complication as a consequence of ovulation in-
duction must be avoided. Current evidence suggests that
OHSS may be prevented if ovarian hyperstimulation is rec-
ognized early by the treating obstetrician (6). In such cases,
many preventive measures can be taken, such as cancelling
the stimulated cycle, coasting (withholding gonadotropins),
aspirating or cauterizing ovarian follicles, or administering
progesterone and steroids (7-10).
Of all possible methods of ovulation induction, The use
of human chorionic gonadotropin is most strongly associated
with the development of OHSS (11). The published litera-
ture suggests that human chorionic gonadotropin plays a
central role in the pathogenesis of OHSS by inducing the
secretion of cytokines and vasoactive mediators, which leads
to increased vascular permeability and third spacing (12).
Intra-abdominal hypertension is also thought to be a key
component in the development of this syndrome and ac-
counts for a number of consequences (13). Additional risk
factors for this syndrome include young age (younger than
35 years), lean build, polycystic ovarian syndrome, history
of atopy or allergies and a past history of OHSS (14-18).
Abdominal distension, abdominal discomfort, nausea,
vomiting and diarrhea are common clinical features of this
syndrome (19). These symptoms result as a consequence of
ovarian stimulation, which results in ovarian enlargement
and the accumulation of exudative ascites (20). Gastrointes-
tinal symptoms are believed to occur due to the effects of
human chorionic gonadotropin (21). Morbidity and mortality
in OHSS results from its complications, which include mas-
sive ascites, pleural effusions, pericardial effusions, electro-
lyte derangements, hemoconcentration, hypovolemia, acute
renal failure, thromboembolic events, neurologic complica-
tions, secondary infections and ovarian hemorrhage, torsion
or even rupture (22-26). The presence of ascites along with
enlarged polycystic ovaries is highly suggestive of the diag-
nosis (27). The differential diagnosis of this disorder in-
cludes all other causes of ascites such as hepatic disorders
(Budd-Chiari syndrome, chronic liver disease, portal vein
thrombosis), renal disorders (nephrotic syndrome), conges-
tive cardiac failure, ovarian tumors, peritoneal metastases
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Figure?2.?The graph depicts the timeline of the patient’s fever and events during the course of ad-
mission.
and abdominal infections (tuberculosis) (1, 28, 29).
Secondary infection is a recognized complication of
OHSS and bacterial peritonitis in association with OHSS
has been reported in the literature (1). Escherichia coli,
Pseudomonas aeruginosa, Klebsiella pneumoniae, Proteus
mirabilis and Proteus vulgaris have been reported to be the
most common pathogens in such cases (1, 19, 30). However,
our patient developed bacterial peritonitis secondary to
Stenotrophomonas maltophilia, a very uncommon pathogen.
This gram-negative rod is commonly implicated in noso-
comial infections; however, it may rarely be community-
acquired (31). In the present case, this organism was either
acquired from the hospital (likely source being the ascitic
drain) or from the community. Although fever developed
early in our patient (Fig. 2), the presence of an ascitic drain
made a nosocomial infection more likely as the route of in-
fection.
The management of OHSS is primarily supportive and
consists of close monitoring of volume status (urinary cathe-
ter and central venous line), judicious fluid therapy, prophy-
lactic or therapeutic anti-coagulation, ventilatory support (if
needed) and therapeutic paracentesis (to relieve intra-
abdominal pressure) (1, 19, 32, 33). To facilitate the man-
agement of this disorder, OHSS has been classified in a
number of ways. One commonly used classification divides
OHSS into moderate (abdominal distension with enlarged,
polycystic ovaries), severe (hemoconcentration or the pres-
ence of large ascites with pleural or pericardial effusions) or
life-threatening (renal failure, tense ascites, neurologic and/
or thromboembolic complications) (34, 35). Prompt recogni-
tion of secondary infections, especially bacterial peritonitis,
is important to institute early antibiotic therapy and prevent
the development of septic shock (36). With adequate treat-
ment of this condition, the mortality is only 1 in 450,000
patients (1).
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